Quercetin induces HepG2 cell apoptosis by inhibiting fatty acid biosynthesis

Oncology Letters

Volumn 8, Issue 2, 2014, Pages 765-769

  Zhao, Peng ^a   Mao, Jun Min ^b   Zhang, Shu Yun ^b   Zhou, Ze Quan ^a   Tan, Yang ^a   Zhang, Yu ^a  

^a Health Management Center Hangzhou Sanatorium of PLA   (China)

^b Department of Traditional Chinese Medicine Hangzhou Sanatorium of PLA ^*  (China)

Author keywords

Apoptosis; Cancer; Fatty acid synthase; HepG2 cells; Quercetin

Indexed keywords

4 [5 (4 METHYL 1 PIPERAZINYL) [2, 5' BI 1H BENZIMIDAZOL] 2' YL] PHENOL; FATTY ACID SYNTHASE; PALMITIC ACID; QUERCETIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL GROWTH; CELL MEMBRANE PERMEABILITY; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOLYSIS; ENZYME ACTIVITY; FATTY ACID ANALYSIS; FATTY ACID SYNTHESIS; GROWTH INHIBITION; HEPG2 CELL LINE; HUMAN; HUMAN CELL; METABOLIC INHIBITION; MTT ASSAY; PROTEIN EXPRESSION; SPECTROPHOTOMETRY; STAINING; WESTERN BLOTTING;

EID: 84902330518     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2159     Document Type: Article

References (52)

1. Alo' PL, Visca P, Marci A, Mangoni A, Botti C and Di Tondo U: Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer 77: 474-482, 1996.
2. Milgraum LZ, Witters LA, Pasternack GR and Kuhajda FP: Enzymes of the fatty acid synthesis pathway are highly expressed in in situ breast carcinoma. Clin Cancer Res 3: 2115-2120, 1997.
3. Epstein JI, Carmichael M and Partin AW: OA-519 (fatty acid synthase) as an independent predictor of pathologic state in adenocarcinoma of the prostate. Urology 45: 81-86, 1995.
4. Swinnen JV, Roskams T, Joniau S, Van Poppel H, Oyen R, Baert L, Heyns W and Verhoeven G: Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int J Cancer 98: 19-22, 2002.
5. Pizer ES, Lax SF, Kuhajda FP, Pasternack GR and Kurman RJ: Fatty acid synthase expression in endometrial carcinoma: correlation with cell proliferation and hormone receptors. Cancer 83: 528-537, 1998.
6. Gansler TS, Hardman W III, Hunt DA, Schaffel S and Hennigar RA: Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. Hum Pathol 28: 686-692, 1997.
7. Rashid A, Pizer ES, Moga M, Milgraum LZ, Zahurak M, Pasternack GR, Kuhajda FP and Hamilton SR: Elevated expression of fatty acid synthase and fatty acid synthetic activity in colorectal neoplasia. Am J Pathol 150: 201-208, 1997.
8. Orita H, Coulter J, Tully E, Kuhajda FP and Gabrielson E: Inhibiting fatty acid synthase for chemoprevention of chemically induced lung tumors. Clin Cancer Res 14: 2458-2464, 2008.
9. Visca P, Sebastiani V, Botti C, Diodoro MG, Lasagni RP, Romagnoli F, Brenna A, De Joannon BC, Donnorso RP, Lombardi G and Alo PL: Fatty acid synthase (FAS) is a marker of increased risk of recurrence in lung carcinoma. Anticancer Res 2: 4169-4173, 2004.
10. Alo PL, Amini M, Piro F, et al: Immunohistochemical expression and prognostic significance of fatty acid synthase in pancreatic carcinoma. Anticancer Res 27: 2523-2527, 2007.
11. Kuhajda FP: Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 16: 202-208, 2000.
12. Walter K, Hong SM, Nyhan S, et al: Serum fatty acid synthase as a marker of pancreatic neoplasia. Cancer Epidem Biomar 18: 2380-2385, 2009.
13. Prieto-Hontoria PL, Pérez-Matute P, Fernández-Galilea M, et al: Role of obesity-associated dysfunctional adipose tissue in cancer: a molecular nutrition approach. Biochim Biophys Acta 1807: 664-678, 2011.
14. Tartter PI, Papatestas AE, Ioannovich J, Mulvihill MN, Lesnick G and Aufses AH Jr: Cholesterol and obesity as prognostic factors in breast cancer. Cancer 47: 2222-2227, 1981.
15. van den Brandt PA, Spiegelman D, Yaun SS, et al: Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol 152: 514-527, 2000.
16. Lahmann PH, Hoffmann K, Allen N, et al: Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 111: 762-771, 2004.
17. Kroenke CH, Chen WY, Rosner B and Holmes MD: Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncol 23: 1370-1378, 2005.
18. Caan BJ, Kwan ML, Hartzell G, et al: Pre-diagnosis body mass index, post-diagnosis weight change, and prognosis among women with early stage breast cancer. Cancer Cause Control 19: 1319-1328, 2008.
19. Dawood S, Broglio K, Gonzalez-Angulo AM, Kau SW, Islam R, Hortobagyi GN and Cristofanilli M: Prognostic value of body mass index in locally advanced breast cancer. Clin Cancer Res 14: 1718-1725, 2008.
20. Calle EE, Rodriguez C, Walker-Thurmond K and Thun MJ: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. New Engl J Med 348: 1625-1638, 2003.
21. Kuhajda FP: Fatty acid synthase and cancer: new application of an old pathway. Cancer Res 66: 5977-5980, 2006.
22. Fan H, Wu D, Tian W and Ma X: Inhibitory effects of tannic acid on fatty acid synthase and 3T3-L1 preadipocyte. Biochim Biophys Acta 1831: 1260-1266, 2013.
23. Wu D, Ma X and Tian W: Pomegranate husk extract, punicalagin and ellagic acid inhibit fatty acid synthase and adipogenesis of 3T3-L1 adipocyte. J Funct Food 5: 633-641, 2013.
24. Wang Y, Tian W and Ma X: Inhibitory effects of onion (Allium cepa L.) extract on proliferation of cancer cells and adipocytes via inhibiting fatty acid synthase. Asian Pacific J Cancer Prev 13: 5573-5579, 2012.
25. Quan X, Wang Y, Ma X, et al: α-Mangostin induces apoptosis and suppresses differentiation of 3T3-L1 cells via inhibiting fatty acid synthase. PLoS One 7: e33376, 2012.
26. Jiang HZ, Ma QY, Fan HJ, et al: Fatty acid synthase inhibitors isolated from Punica granatum L. J Braz Chem Soc 23: 889-893, 2012.
27. Jiang HZ, Quan XF, Tian WX, et al: Fatty acid synthase inhibitors of phenolic constituents isolated from Garcinia mangostana. Bioorg Med Chem Lett 20: 6045-6047, 2010.
28. Fan H, Tian W and Ma X: Curcumin induces apoptosis of HepG2 cells via inhibiting fatty acid synthase. Targ Oncol: Jul 3, 3013 (Epub ahead of print). doi: 10.1007/s11523-013-0286-5.
29. Erlund I: Review of the flavonoids quercetin, hesperetin, and naringenin. Dietary sources, bioactivities, bioavailability, and epidemiology. Nutr Res 24: 851-874, 2004.
30. Gibellini L, Pinti M, Nasi M, et al: Quercetin and cancer chemoprevention. Evid Based Complement Alternat Med 2011: 591356, 2011.
31. Park MH and Min do S: Quercetin-induced downregulation of phospholipase D1 inhibits proliferation and invasion in U87 glioma cells. Biochem Biophys Res Commun 412: 710-715, 2011.
32. Du G, Lin H, Wang M, et al: Quercetin greatly improved therapeutic index of doxorubicin against 4T1 breast cancer by its opposing effects on HIF-1α in tumor and normal cells. Cancer Chemother Pharmacol 65: 277-287, 2010.
33. Leiherer A, Mündlein A and Drexel H: Phytochemicals and their impact on adipose tissue inflammation and diabetes. Vascul Pharmacol 58: 3-20, 2013.
34. Hurt RT and Wilson T: Geriatric obesity: evaluating the evidence for the use of flavonoids to promote weight loss. J Nutr Gerontol Geriatr 31: 269-289, 2012.
35. Arçari DP, Santos JC, Gambero A and Ribeiro ML: The in vitro and in vivo effects of yerba mate (Ilex paraguariensis) extract on adipogenesis. Food Chem 141: 809-815, 2013.
36. Uddin S, Ah-Kang J, Ulaszek J, Mahmud D and Wickrema A: Differentiation stage-specific activation of p38 mitogen-activated protein kinase isoforms in primary human erythroid cells. Proc Natl Acad Sci USA 101: 147-152, 2004.
37. Menendez JA, Mehmi I, Atlas E, Colomer R and Lupu R: Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB. Int J Oncol 24: 591-608, 2004.
38. Angst E, Park JL, Moro A, et al: The flavonoid quercetin inhibits pancreatic cancer growth in vitro and in vivo. Pancreas 42: 223-229, 2013.
39. Del Follo-Martinez A, Banerjee N, Li X, Safe S and Mertens-Talcott S: Resveratrol and quercetin in combination have anticancer activity in colon cancer cells and repress oncogenic microRNA-27a. Nutr Cancer 65: 494-504, 2013.
40. Berndt K, Campanile C, Muff R, Strehler E, Born W and Fuchs B: Evaluation of quercetin as a potential drug in osteosarcoma treatment. Anticancer Res 33: 1297-1306, 2013.
41. Gao X, Wang B, Wei X, et al: Anticancer effect and mechanism of polymer micelle-encapsulated quercetin on ovarian cancer. Nanoscale 4: 7021-7030, 2012.
42. Lai WW, Hsu SC, Chueh FS, et al: Quercetin inhibits migration and invasion of SAS human oral cancer cells through inhibition of NF-κB and matrix metalloproteinase-2/-9 signaling pathways. Anticancer Res 33: 1941-1950, 2013.
43. Lam TK, Shao S, Zhao Y, et al: Influence of quercetin-rich food intake on microRNA expression in lung cancer tissues. Cancer Epidemiol Biomarkers Prev 21: 2176-2184, 2012.
44. Zhang SY, Ma XF, Zheng CG, Wang Y, Cao XL and Tian WX: Novel and potent inhibitors of fatty acid synthase derived from catechins and their inhibition on MCF-7 cells. J Enzyme Inhib Med Chem 24: 623-631, 2009.
45. Li P, Tian W, Wang X and Ma X: Inhibitory effect of desoxyrhaponticin and rhaponticin, two natural stilbene glycosides from the Tibetan medicinal plant Rheum tanguticum Maxim. ex Balf., on fatty acid synthase and human breast cancer cells. Food Funct 5: 251-256, 2014.
46. Li BH and Tian WX: Inhibitory effects of flavonoids on animal fatty acid synthase. J Biochem 135: 85-91, 2004.
47. Aggarwal BB and Shishodia S: Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 71: 1397-1421, 2006.
48. Bandyopadhyay S, Pai SK, Watabe M, et al: FAS expression inversely correlates with PTEN level in prostate cancer and a PI3-kinase inhibitor synergizes with FAS siRNA to induce apoptosis. Oncogene 24: 5389-5395, 2005.
49. Menendez JA and Lupu R: Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nature Rev Cancer 7: 763-777, 2007.
50. Pizer ES, Thupari J, Han WF, et al: Malonyl-coenzymeA is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts. Cancer Res 60: 213-218, 2000.
51. Zhou W, Simpson PJ, McFadden JM, et al: Fatty acid synthase inhibition triggers apoptosis during S phase in human cancer cells. Cancer Res 63: 7330-7337, 2003.
52. Murthy S, Albright E, Mathur SN and Field FJ: Modification of CaCo-2 cell membrane fatty acid composition by eicosapentaenoic acid and palmitic acid: effect on cholesterol metabolism. J Lipid Res 29: 773-780. 1988.